Back to discover
Disease

Ocular Hypertension

Late-stage therapeutic developmentEmerging research
MeSHOcular Hypertension
1
Publications
22
Clinical trials
12
Associated genes
5
Related proteins
2021
Latest publication
Current focus
Beta-2 adrenergic biologyProstaglandin f2-alpha biologyTherapeutic development
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones8View
Results expected 4
Other updates 4
Industry & Market2View
Activity timeline10

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Latanoprostapproved

Original application approval — Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult… (2023)

Netarsudilapproved

Original application approval — Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angl… (2019)

Travoprostapproved

Original application approval — Decrease of elevated intraocular pressure in adult patients with ocular hypertension or o… (2014)

Bimatoprostapproved

Original application approval — Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hype… (2002)

Brinzolamideapproved

Original application approval — Azopt is indicated to decrease elevated intraocular pressure in: ocular hypertension; op… (2000)

Clinical trials

13 sponsors · 4 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
22
All trials
5
Active
16
Late-stage
5
Completed
Late-stage studies

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

Phase 3 · Recruiting · Liquidia Technologies, Inc.

Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease

Phase 3 · Active, not recruiting · Liquidia Technologies, Inc.

Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial

Phase 4 · Recruiting · Beijing Anzhen Hospital

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Phase 3 · Recruiting · Inhibikase Therapeutics

A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Phase 4 · Completed · Boryung Pharmaceutical Co., Ltd
Recruiting

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

Phase 3 · Recruiting · Liquidia Technologies, Inc.

Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial

Phase 4 · Recruiting · Beijing Anzhen Hospital

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Phase 3 · Recruiting · Inhibikase Therapeutics
Recently completed

A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients

Phase 4 · Completed · Boryung Pharmaceutical Co., Ltd

A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.

Phase 3 · Completed · LG Life Sciences

An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension

Phase 3 · Completed · Boehringer Ingelheim

An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Single Pill (SPC) Combination of Aliskiren 300 mg / Amlodipine 10 mg in Hypertensive Patients Not Adequately Respond to an Uptitrated 4 Week Therapy With the SPC of Olmesartan 40 mg / Amlodipine 10 mg, With a Potential Extension if Patients Still Not Adequately Respond With a 4 Week Therapy With the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg

Phase 3 · Completed · Novartis

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

Substantial evidence coverage
66% · 73/111 eligible items incorporated
lowers systolic blood pressure in hypertension65%
lowers diastolic blood pressure in hypertension65%

Largest gap: no meaningful change (9, trial-readability).

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2023emaOriginal application approval — Latanoprost· Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma.   source ↗
2019emaOriginal application approval — Netarsudil· Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension. source ↗
2014emaOriginal application approval — Travoprost· Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma. source ↗
2002emaOriginal application approval — Bimatoprost· Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers). source ↗
2001emaOriginal application approval — Travoprost· Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1). source ↗
2000emaOriginal application approval — Brinzolamide· Azopt is indicated to decrease elevated intraocular pressure in: ocular hypertension; open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition.

The British journal of ophthalmology · 2021 · 419 cites
Recent publications

European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition.

The British journal of ophthalmology · 2021 · 419 cites
Major themes3
  • Glaucoma1
  • Glaucoma, Angle-Closure1
  • Glaucoma, Open-Angle1
Leading journals1
  • The British journal of ophthalmology1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

PTGFR0.61ADRB20.61CA20.61ADRB10.61ROCK10.59PTGER20.54KIF20B0.35GCFC20.35CES5A0.35ZNRF40.34DENND5A0.34TUT70.32

Disease biology

5 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Prostaglandin F2-alpha receptorvia PTGFR0.61Beta-2 adrenergic receptorvia ADRB20.61Carbonic anhydrase 2via CA20.61Beta-1 adrenergic receptorvia ADRB10.61Prostaglandin E2 receptor EP2 subtypevia PTGER20.54

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.

Identifiers
MeSHOcular Hypertension
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.